Study on drug retention of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder

doi:10.5246/jcps.2022.10.065

Abstract

Abstract:

This study retrospectively analyzed the medication prescriptions of children diagnosed with attention-deficit/hyperactivity disorder (ADHD) in Ningbo Psychiatric Hospital and Ningbo Women and Children’s Hospital from March 2018 to September 2020 and compared the drug retention rate of methylphenidate hydrochloride and atomoxetine hydrochloride. The prescription automatic screening system was used to screen the prescriptions in children with ADHD. Kaplan-Meier regression analysis was used to compare prescription retention rates between the two regimens after adjusting for gender, age, body weight, and prescription cost. The mean age of the methylphenidate hydrochloride group was 8.75 ± 2.16 years, and the monthly prescription cost was 327.37 ± 146.64 RMB. The average age of the atomoxetine group was 8.33 ± 1.73 years, and the monthly prescription cost was 363.15 ± 154.90 ￥. There were some differences in the age of enrollment and the monthly prescription cost between the two regimens (all P < 0.01). Moreover, the retention rate of methylphenidate hydrochloride was higher compared with atomoxetine hydrochloride within 18 months. Kaplan-Meier regression analysis showed that this trend was significant (Tarone-ware, Chi-square value = 14.893, P < 0.001). Prescription costs might be a factor affecting drug retention. This study found that the retention rates were decreased month by month in children with ADHD, and after 5 months, the retention rates were 52.20% and 41.22%, respectively, far below the recommended levels of the guidelines.

Key words: Attention-deficit/hyperactivity disorder, Methylphenidate, Tomoxetine, Drug retention rate

Supporting:

Li Yu, Chaohui Ye. Study on drug retention of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(10): 755-760.

Figures/Tables 4

References 16

[1]	Wolraich, M.L.; Chan, E.; Froehlich, T.; Lynch, R.L.; Bax, A.; Redwine, S.T.; Ihyembe, D.; Hagan, J.F. Jr. ADHD diagnosis and treatment guidelines: a historical perspective. Pediatrics. 2019, 144, 1682–1690.
[2]	Biederman, J.; Faraone, S.V. Attention-deficit hyperactivity disorder. Lancet. 2005, 366, 237–248.
[3]	Wang, T.T.; Liu, K.H.; Li, Z.Z.; Xu, Y.; Liu, Y.; Shi, W.P.; Chen, L.Z. Prevalence of attention deficit/hyperactivity disorder among children and adolescents in China: a systematic review and meta-analysis. BMC Psychiatry. 2017, 17, 32–42.
[4]	Subspecialty Group of Developmental and Behavioral Pediatrics, T.S.O.P. Consensus on pediatric clinical practice of early identification, standardized diagnosis and treatment of attention deficit hyperactivity disorder. Chin. J. Pediatrics. 2020, 58, 188–193.
[5]	Posner, J.; Polanczyk, G.V.; Sonuga-Barke, E. Attention-deficit hyperactivity disorder. Lancet. 2020, 395, 450–462.
[6]	Deng, L.L.; Zhou, P.; Zhu, L.; Zhang, Y.; Yang, T.; Zhao, Q.X.; Chen, J.; Li, T.Y.; Cheng, Q.; Chen, L. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder. Pharmacol. Biochem. Behav. 2021, 208, 173225.
[7]	Zablotsky, B.; Bramlett, M.D.; Blumberg, S.J. The co-occurrence of autism spectrum disorder in children with ADHD. J. Atten. Disord. 2020, 24, 94–103.
[8]	Gajria, K.; Lu, M.; Sikirica, V.; Greven, P.; Zhong, Y.C.; Qin, P.G.; Xie, J.P. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr. Dis. Treat. 2014, 10, 1543–1569.
[9]	Zetterqvist, J.; Asherson, P.; Halldner, L.; Långström, N.; Larsson, H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr. Scand. 2013, 128, 70–77.
[10]	Shao, S.R.; Shao, X.Q.; Chen, Y. Study on drug retention in menopausal women with sequential hormone therapy and tibolone. J. Chin. Pharm. Sci. 2020, 29, 649–655.
[11]	Association, A.P. Diagnostic and statistical manual of mental disorders fifth edition (dSM⁃5). American Psychiatric. Pub. 2013, 59–65.
[12]	Dalsgaard, S.; Leckman, J.F.; Mortensen, P.B.; Nielsen, H.S.; Simonsen, M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015, 2, 702–709.
[13]	Caye, A.; Spadini, A.V.; Karam, R.G.; Grevet, E.H.; Rovaris, D.L.; Bau, C.H.D.; Rohde, L.A.; Kieling, C. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur. Child Adolesc. Psychiatry. 2016, 25, 1151–1159.
[14]	Wigal, S.B.; Hopkins, S.C.; Koblan, K.S.; Childress, A.; Kent, J.M.; Tsai, J.; Hsu, J.; Loebel, A.; Goldman, R. Efficacy and safety of dasotraline in children with ADHD: a laboratory classroom study. J. Atten. Disord. 2020, 24, 192–204.
[15]	Sharma, A.; Couture, J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann. Pharmacother. 2014, 48, 209–225.
[16]	Childress, A.C. A critical appraisal of atomoxetine in the management of ADHD. Ther. Clin. Risk Manag. 2016, 12, 27–39.